Overview

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Status:
Completed
Trial end date:
2014-12-20
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
Phase:
Phase 3
Details
Lead Sponsor:
Allergan
Treatments:
Olopatadine Hydrochloride
Ophthalmic Solutions